Efficacy of low radioiodine activity versus intermediate-high activity in the ablation of low-risk differentiated thyroid cancer

D Albano, M Bonacina, R Durmo, F Bertagna… - Endocrine, 2020 - Springer
Purpose The aim of our study was to compare the efficacy of thyroid remnant ablation using
low (1.1 GBq) and intermediate-high radioiodine (RAI) activity (1.85–3.7 GBq) in low-risk …

[HTML][HTML] Less than 2% of the low-and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan

L Agate, F Bianchi, F Brozzi, P Santini… - European Thyroid …, 2019 - etj.bioscientifica.com
Background: Recently, there has been a trend to reduce the use of radioiodine remnant
ablation (RRA) in patients with low-risk (LR) and intermediate-risk (IR) differentiated thyroid …

Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer

Y Iizuka, T Katagiri, K Ogura, T Mizowaki - Annals of Nuclear Medicine, 2019 - Springer
Objective This study aimed to compare the clinical outcomes of patients who received
radioactive iodine (RAI) ablation after undergoing thyroidectomy for intermediate-to-high-risk …

Radioiodine remnant ablation in low‐risk differentiated thyroid cancer patients who had R0 dissection is an over treatment

C Bal, S Ballal, R Soundararajan, S Chopra… - Cancer …, 2015 - Wiley Online Library
Low‐risk (LR) differentiated thyroid cancer (DTC) patients should be ablated or not, albeit,
with small dose of radioiodine is highly controversial. We hypothesized that those LR DTC …

Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence

PW Rosario, MS Furtado, AFCM Filho, RX Lacerda… - Thyroid, 2012 - liebertpub.com
Background: Diagnostic radioiodine whole-body scanning (DxWBS) in combination with
stimulated thyroglobulin (Tg)(ie, measurement after levothyroxine [L-T4] withdrawal or …

Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature

L Lamartina, C Durante, S Filetti… - The Journal of Clinical …, 2015 - academic.oup.com
Background: Radioiodine remnant ablation (RRA) has traditionally been one of the
cornerstones of differentiated thyroid cancer (DTC) treatment. The decision to use RRA in …

Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?

A Piccardo, M Puntoni, G Ferrarazzo, L Foppiani… - European journal of …, 2018 - Springer
Purpose Current guidelines recommend thyroid hormone withdrawal (THW) of 3–4 weeks
before radioiodine remnant ablation (RRA) of differentiated thyroid carcinoma (DTC). We …

[PDF][PDF] Diagnostic whole-body scan may not be necessary for intermediate-risk patients with differentiated thyroid cancer after low-dose (30 mCi) radioactive iodide …

EJ Jeon, E Dal Jung - Endocrinology and Metabolism, 2014 - synapse.koreamed.org
Background: A diagnostic whole-body scan (WBS) is recommended 6 to 12 months after
total thyroidectomy and radioactive iodide ablation in intermediate-or high-risk patients with …

Re-ablation I-131 activity does not predict treatment success in low-and intermediate-risk patients with differentiated thyroid carcinoma

M Prpic, I Kruljac, D Kust, LS Kirigin, T Jukic, N Dabelic… - Endocrine, 2016 - Springer
The aim of this study was to evaluate the efficacy of different radioactive iodine (I-131)
activities used for re-ablation, to compare various combinations of treatment activities, and to …

Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer

L Welsh, C Powell, B Pratt, K Harrington… - The Journal of …, 2013 - academic.oup.com
Context: Randomized trials show that low-dose (1.1 GBq [30 mCi]) radioiodide (RAI) has
efficacy equivalent to high-dose RAI (3.7 GBq [100 mCi]) in thyroid remnant ablation (TRA) …